ACOG Committee Opinion 280 Has Been Superseded by More Current Guidelines
ACOG Committee Opinion 280 is no longer the current standard for adnexal mass triage—it has been replaced by ACOG Practice Bulletin No. 174 (2016) and more recently by contemporary risk stratification systems including O-RADS, IOTA simple rules, and the SRU consensus statement. 1
Evolution of Adnexal Mass Assessment
The landscape of adnexal mass evaluation has evolved significantly beyond the original Committee Opinion 280:
Current Standard Approaches
Modern practice now relies on validated, standardized risk stratification systems rather than the older ACOG 280 criteria. The most widely adopted contemporary systems include:
O-RADS (Ovarian-Adnexal Reporting and Data System): Demonstrates 96.8% sensitivity for malignancy with 92.8% specificity, outperforming older classification systems 1
IOTA Simple Rules: Shows 92.1% sensitivity with 93.2% specificity 1
SRU Consensus Statement: Proven to decrease unnecessary follow-up of benign lesions while maintaining high sensitivity and specificity for detecting malignancy 1
What Replaced ACOG 280
ACOG Practice Bulletin No. 174 (2016) is the current ACOG guideline for evaluation and management of adnexal masses 2. This bulletin provides updated criteria for identifying masses requiring referral to gynecologic oncology.
Current Referral Criteria to Gynecologic Oncology
Based on contemporary evidence, refer when patients have 3, 4:
Postmenopausal women with:
- Elevated CA-125
- Nodular or fixed pelvic mass
- Evidence of metastatic disease
- Ascites
- Family history of breast or ovarian cancer
Premenopausal women with:
- CA-125 >200 U/mL
- Evidence of metastatic disease
- Ascites
- Strong family history of breast or ovarian cancer
Clinical Performance
Recent data shows that 84.7% of adnexal mass referrals to gynecologic oncology meet current ACOG referral criteria, with this proportion increasing to 92.6% by 2021, suggesting improved adherence to contemporary guidelines 3.
Practical Algorithm
Use transvaginal ultrasound as first-line imaging (>90% sensitivity), combined with transabdominal approach for larger lesions 1. Apply O-RADS classification using grayscale morphology plus color Doppler (color score 1-4) to stratify malignancy risk. Lesions classified as O-RADS 4 or 5 warrant gynecologic oncology referral, while O-RADS 1-3 can typically be managed by general gynecology with appropriate surveillance.
Common Pitfall
Do not continue using outdated Committee Opinion 280 criteria when current validated systems (O-RADS, IOTA, Practice Bulletin 174) provide superior diagnostic performance and are now the accepted standard of care.